Related Experiment Video
Updated: Feb 27, 2026
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
Published on: September 5, 2025
Site-1 protease, a novel metabolic target for glioblastoma
Beth T Caruana1, Aleksandra Skoric1, Andrew J Brown1
1School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Australia.
Abstract:
Sterol regulatory element binding proteins (SREBPs) are transcriptional regulators of lipids which promote glioblastoma growth. Here, we investigate the effect of inhibiting expression of SREBP target genes in human glioblastoma cells. This was achieved by using PF-429242 to inhibit site-1 protease (S1P), an enzyme required for SREBP activation. Treatment with PF-429242 decreased glioblastoma cell viability, induced apoptosis and downregulated steroid, isoprenoid and unsaturated fatty acid biosynthetic pathways. Several pro-inflammatory genes were upregulated. Collectively, these results demonstrate the potential of S1P as a target for glioblastoma therapy.
Insights
Inhibiting sterol regulatory element binding proteins (SREBPs) via site-1 protease (S1P) inhibition reduced glioblastoma cell growth. This targeted approach shows promise for glioblastoma treatment by disrupting lipid synthesis pathways.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Sterol regulatory element binding proteins (SREBPs) are key transcriptional regulators of lipid metabolism.
- SREBPs promote the growth and progression of glioblastoma (GBM), a highly aggressive brain tumor.
- Targeting lipid synthesis pathways is a potential therapeutic strategy for GBM.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting SREBP activity in human glioblastoma cells.
- To evaluate the effects of blocking site-1 protease (S1P), essential for SREBP activation, on glioblastoma cells.
Main Methods:
- Utilized PF-429242, a specific inhibitor of site-1 protease (S1P).
- Treated human glioblastoma cell lines with PF-429242.
- Assessed changes in cell viability, apoptosis, and the expression of genes involved in lipid biosynthesis and inflammation.
Main Results:
- PF-429242 treatment significantly decreased glioblastoma cell viability.
- Inhibition of S1P led to increased apoptosis in glioblastoma cells.
- Downregulation of steroid, isoprenoid, and unsaturated fatty acid biosynthesis pathways was observed.
- Upregulation of several pro-inflammatory genes was noted.
Conclusions:
- Site-1 protease (S1P) is a critical enzyme for SREBP activation in glioblastoma.
- Inhibiting S1P with PF-429242 demonstrates anti-cancer effects in glioblastoma models.
- S1P inhibition represents a promising therapeutic target for glioblastoma treatment by disrupting essential lipid metabolic pathways.
